Health Canada gives 'kiss of death' to planned policy for rare-disease drugs
OTTAWA — Health Canada has quietly deleted from its website all references to a planned framework for rare-disease drugs that dates back to 2012 and was intended to improve the availability of such drugs in Canada. Canada is one of the only developed countries without a regulatory framework for rare-disease drugs, also known as orphan drugs.
Balloon pulmonary angioplasty may improve hemodynamic results in CTEPH
Balloon pulmonary angioplasty may be a viable option for patients with chronic thromboembolic pulmonary hypertension who were ineligible for pulmonary endarterectomy, according to results from a multicenter registry.
OHIP+: Children and Youth Pharmacare: An update on public drug coverage for PH medications for youth in Ontario
Earlier this year, the government of Ontario announced the expansion of the Ontario Health Insurance Program (OHIP) to include coverage of all children and youth aged 24 and younger. Starting January 01, 2018, drug products currently available through the Ontario Drug Benefit Program will be free to everyone under the age of 25. Medications currently available through the Exceptional Access Program – including treatments for pulmonary hypertensio…
Legacy of Alberta girl with rare disease lives on in new documentary
She died much too early, but an Edmonton girl continues to brighten lives after her passing. Her family is making sure her legacy lives on in a new documentary. Su-Ling Goh has Sophia Syskakis' story.
Lung cancer triggers pulmonary hypertension
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart and Lung Research in Bad Nauheim and the German Center for Lung Research found after examining more than 500 patients. The pulmonary hypertension observed is possibly due to immune and inflammatory processes triggered by canc…
Pulmonary Hypertension Association of Canada launches Life in Purple Challenge Campaign for Pulmonary Hypertension Awareness Month
Vancouver, BC (November 7, 2017) ? The Pulmonary Hypertension Association of Canada (PHA Canada) is celebrating Pulmonary Hypertension Awareness Month this November with the launch of the Life in Purple Challenge. This new awareness and fundraising campaign highlights the impacts of pulmonary hypertension (PH) on the everyday lives of patients and caregivers. PH is a rare but very complex and serious lung disease that is progressive and potential…
PHA Fundraising Campaign Asks Canadians to ‘Walk in the Shoes’ of PH Patients
The Pulmonary Hypertension Association of Canada has launched its Life in Purple Challenge campaign to mark November, Pulmonary Hypertension Awareness Month.
PDE5 Blocker May Be an Effective Therapy for Early PH After Heart Attack, Study Suggests
Blocking the enzyme phosphodiesterase 5 (PDE5) is a potential new therapeutic strategy to treat early pulmonary hypertension (PH) in patients who have had a heart attack, a study suggests. The research, “Pulmonary vasodilation by phosphodiesterase 5-inhibition is enhanced and nitric oxide-independent in early pulmonary hypertension after myocardial infarction,” was published in the The American Journal of Physiology-Heart and Circulatory Physi…
New hope for pulmonary hypertension thanks to old drug
Researchers in Alberta may have found a new use for an old generic drug: treating pulmonary arterial hypertension (PAH).
New device helps treat pulmonary hypertension
A new device, the Third Pole is able to generate nitric oxide (NO) from the air that can help improve oxygenation and treat pulmonary hypertension a common problem among some newborns.
Recent News


Get the latest on PH treatments, community events and more when you subscribe to our newsletter